Cargando…

Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB

BACKGROUND: Mucopolysaccharidosis type IIIB (MPS IIIB) is a rare genetic disorder in which the deficiency of the lysosomal enzyme N-acetyl-α-glucosaminidase (NAGLU) results in the accumulation of heparan sulfate (HS), leading to progressive neurocognitive deterioration. In MPS IIIB a wide spectrum o...

Descripción completa

Detalles Bibliográficos
Autores principales: Meijer, O. L. M., Welling, L., Valstar, M. J., Hoefsloot, L. H., Brüggenwirth, H. T., van der Ploeg, A. T., Ruijter, G. J. G., Wagemans, T., Wijburg, F. A., van Vlies, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851702/
https://www.ncbi.nlm.nih.gov/pubmed/26907177
http://dx.doi.org/10.1007/s10545-016-9916-2
_version_ 1782429847779278848
author Meijer, O. L. M.
Welling, L.
Valstar, M. J.
Hoefsloot, L. H.
Brüggenwirth, H. T.
van der Ploeg, A. T.
Ruijter, G. J. G.
Wagemans, T.
Wijburg, F. A.
van Vlies, N.
author_facet Meijer, O. L. M.
Welling, L.
Valstar, M. J.
Hoefsloot, L. H.
Brüggenwirth, H. T.
van der Ploeg, A. T.
Ruijter, G. J. G.
Wagemans, T.
Wijburg, F. A.
van Vlies, N.
author_sort Meijer, O. L. M.
collection PubMed
description BACKGROUND: Mucopolysaccharidosis type IIIB (MPS IIIB) is a rare genetic disorder in which the deficiency of the lysosomal enzyme N-acetyl-α-glucosaminidase (NAGLU) results in the accumulation of heparan sulfate (HS), leading to progressive neurocognitive deterioration. In MPS IIIB a wide spectrum of disease severity is seen. Due to a large allelic heterogeneity, establishing genotype-phenotype correlations is difficult. However, reliable prediction of the natural course of the disease is needed, in particular for the assessment of the efficacy of potential therapies. METHODS: To identify markers that correlate with disease severity, all Dutch patients diagnosed with MPS IIIB were characterised as either rapid (RP; classical, severe phenotype) or slow progressors (SP; non-classical, less severe phenotype), based on clinical data. NAGLU activity and HS levels were measured in patients’ fibroblasts after culturing at different temperatures. RESULTS: A small, though significant difference in NAGLU activity was measured between RP and SP patients after culturing at 37 °C (p < 0.01). Culturing at 30 °C resulted in more pronounced and significantly higher NAGLU activity levels in SP patients (p < 0.001) with a NAGLU activity of 0.58 nmol.mg-1.hr-1 calculated to be the optimal cut-off value to distinguish between the groups (sensitivity and specificity 100 %). A lower capacity of patients’ fibroblasts to increase NAGLU activity at 30 °C could significantly predict for the loss of several disease specific functions. CONCLUSION: NAGLU activity in fibroblasts cultured at 30 °C can be used to discriminate between RP and SP MPS IIIB patients and the capacity of cells to increase NAGLU activity at lower temperatures correlates with disease symptoms.
format Online
Article
Text
id pubmed-4851702
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-48517022016-05-19 Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB Meijer, O. L. M. Welling, L. Valstar, M. J. Hoefsloot, L. H. Brüggenwirth, H. T. van der Ploeg, A. T. Ruijter, G. J. G. Wagemans, T. Wijburg, F. A. van Vlies, N. J Inherit Metab Dis Original Article BACKGROUND: Mucopolysaccharidosis type IIIB (MPS IIIB) is a rare genetic disorder in which the deficiency of the lysosomal enzyme N-acetyl-α-glucosaminidase (NAGLU) results in the accumulation of heparan sulfate (HS), leading to progressive neurocognitive deterioration. In MPS IIIB a wide spectrum of disease severity is seen. Due to a large allelic heterogeneity, establishing genotype-phenotype correlations is difficult. However, reliable prediction of the natural course of the disease is needed, in particular for the assessment of the efficacy of potential therapies. METHODS: To identify markers that correlate with disease severity, all Dutch patients diagnosed with MPS IIIB were characterised as either rapid (RP; classical, severe phenotype) or slow progressors (SP; non-classical, less severe phenotype), based on clinical data. NAGLU activity and HS levels were measured in patients’ fibroblasts after culturing at different temperatures. RESULTS: A small, though significant difference in NAGLU activity was measured between RP and SP patients after culturing at 37 °C (p < 0.01). Culturing at 30 °C resulted in more pronounced and significantly higher NAGLU activity levels in SP patients (p < 0.001) with a NAGLU activity of 0.58 nmol.mg-1.hr-1 calculated to be the optimal cut-off value to distinguish between the groups (sensitivity and specificity 100 %). A lower capacity of patients’ fibroblasts to increase NAGLU activity at 30 °C could significantly predict for the loss of several disease specific functions. CONCLUSION: NAGLU activity in fibroblasts cultured at 30 °C can be used to discriminate between RP and SP MPS IIIB patients and the capacity of cells to increase NAGLU activity at lower temperatures correlates with disease symptoms. Springer Netherlands 2016-02-23 2016 /pmc/articles/PMC4851702/ /pubmed/26907177 http://dx.doi.org/10.1007/s10545-016-9916-2 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Meijer, O. L. M.
Welling, L.
Valstar, M. J.
Hoefsloot, L. H.
Brüggenwirth, H. T.
van der Ploeg, A. T.
Ruijter, G. J. G.
Wagemans, T.
Wijburg, F. A.
van Vlies, N.
Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB
title Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB
title_full Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB
title_fullStr Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB
title_full_unstemmed Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB
title_short Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB
title_sort residual n-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type iiib
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851702/
https://www.ncbi.nlm.nih.gov/pubmed/26907177
http://dx.doi.org/10.1007/s10545-016-9916-2
work_keys_str_mv AT meijerolm residualnacetylaglucosaminidaseactivityinfibroblastscorrelateswithdiseaseseverityinpatientswithmucopolysaccharidosistypeiiib
AT wellingl residualnacetylaglucosaminidaseactivityinfibroblastscorrelateswithdiseaseseverityinpatientswithmucopolysaccharidosistypeiiib
AT valstarmj residualnacetylaglucosaminidaseactivityinfibroblastscorrelateswithdiseaseseverityinpatientswithmucopolysaccharidosistypeiiib
AT hoefslootlh residualnacetylaglucosaminidaseactivityinfibroblastscorrelateswithdiseaseseverityinpatientswithmucopolysaccharidosistypeiiib
AT bruggenwirthht residualnacetylaglucosaminidaseactivityinfibroblastscorrelateswithdiseaseseverityinpatientswithmucopolysaccharidosistypeiiib
AT vanderploegat residualnacetylaglucosaminidaseactivityinfibroblastscorrelateswithdiseaseseverityinpatientswithmucopolysaccharidosistypeiiib
AT ruijtergjg residualnacetylaglucosaminidaseactivityinfibroblastscorrelateswithdiseaseseverityinpatientswithmucopolysaccharidosistypeiiib
AT wagemanst residualnacetylaglucosaminidaseactivityinfibroblastscorrelateswithdiseaseseverityinpatientswithmucopolysaccharidosistypeiiib
AT wijburgfa residualnacetylaglucosaminidaseactivityinfibroblastscorrelateswithdiseaseseverityinpatientswithmucopolysaccharidosistypeiiib
AT vanvliesn residualnacetylaglucosaminidaseactivityinfibroblastscorrelateswithdiseaseseverityinpatientswithmucopolysaccharidosistypeiiib